systhiperСистемные гипертензииSystemic Hypertension2075-082X2542-2189LLC «ИнтерМедсервис»systhiper-334Research ArticleКАРДИОЛОГИЯCARDIOLOGYМесто блокаторов рецепторов ангиотензина в антигипертензивной терапииPlace of angiotensin receptor blockers in antihypertensive therapyМартыновА. И.MartynovA. I.noemail@neicon.ruУрлаеваИ. В.UrlaevaI. V.noemail@neicon.ruАкатоваЕ. В.AkatovaE. V.noemail@neicon.ruНиколинО. П.NikolinO. P.noemail@neicon.ruГБОУ ВПО Московский государственный медико-стоматологический университет им. А.И.Евдокимова Минздрава РоссииRussian Federation2014231220221113439Copyright © Мартынов А.И., Урлаева И.В., Акатова Е.В., Николин О.П., 20222022Мартынов А.И., Урлаева И.В., Акатова Е.В., Николин О.П.Martynov A.I., Urlaeva I.V., Akatova E.V., Nikolin O.P.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.syst-hypertension.ru/jour/article/view/334

Артериальная гипертензия занимает основное место среди сердечно-сосудистых заболеваний, являющихся основной причиной смерти и нетрудоспособности. На сегодняшний день основной группой препаратов для лечения артериальной гипертензии остаются ингибиторы ангиотензинпревращающего фермента (ИАПФ). По данным многочисленных исследований, блокаторы рецепторов ангиотензина II по своей эффективности равны ИАПФ, однако они имеют лучший профиль переносимости и обеспечивают более высокую приверженность терапии. Одним из высокоэффективных, хорошо изученных препаратов со значительной доказательной базой является ирбесартан.

The arterial hypertension takes the basic place among the cardiovascular diseases which are a principal cause of death and invalidity. For today the basic group for treatment of an arterial hypertensia remain angiotensin-converting enzyme inhibitors (ACEi). However, according to numerous researches, angiotensin II receptor inhibitors by the efficiency are equal with ACEi, but have the best profile of shipping and provide higher adherence to therapy. One of highly effective, well studied, with considerable demonstrative base of preparations irbesartan.

артериальная гипертензияренин-ангиотензиновая системаблокаторы рецепторов ангиотензина IIирбесартанarterial hypertensionrenin-angiotenzin systemangiotensin II receptor inhibitorsirbesartanReferencesДиагностика и лечение артериальной гипертензии. Кардиоваск. терапия и профилактика. 2008; 7 (6). Прил. 2.Диагностика и лечение артериальной гипертензии. Кардиоваск. терапия и профилактика. 2008; 7 (6). Прил. 2.ESH-ESC Guidelines Committee. 2007 Guidelines for the management of arterial hypertension. J Hypertension 2007; 25: 1105-87.ESH-ESC Guidelines Committee. 2007 Guidelines for the management of arterial hypertension. J Hypertension 2007; 25: 1105-87.Neutel J et al. Comparison of Monotherapy with Irbesartan 150 mg or Amlodipine 5 mg for Treatment of Mild - to - Moderate Hypertension.J RAAS 2005; 6: 84-9.Neutel J et al. Comparison of Monotherapy with Irbesartan 150 mg or Amlodipine 5 mg for Treatment of Mild - to - Moderate Hypertension.J RAAS 2005; 6: 84-9.Mimran A et al. A rindomised, double - blind comparison of the angiotensin II receptor antagonist, irbesartan, with the full dose range of enalapril for the treatment of mild - to - moderate hypertension. J Hum Hypertens 1998; 12: 203-8.Mimran A et al. A rindomised, double - blind comparison of the angiotensin II receptor antagonist, irbesartan, with the full dose range of enalapril for the treatment of mild - to - moderate hypertension. J Hum Hypertens 1998; 12: 203-8.Stumpe K.O et al. Comparison of the Angiotensin II Receptor Antagonist Irbesartan With Atenolol for Treatment of Hypertension Blood Press 1998; 7: 31-7.Stumpe K.O et al. Comparison of the Angiotensin II Receptor Antagonist Irbesartan With Atenolol for Treatment of Hypertension Blood Press 1998; 7: 31-7.Mancia G et al. An ambulatory blood pressure monitoring study of the comparative antihypertensive efcacy of two angiotensin II receptor antagonists, irbesartan and valsartan. Blood Press Monit 2002; 7: 135-42.Mancia G et al. An ambulatory blood pressure monitoring study of the comparative antihypertensive efcacy of two angiotensin II receptor antagonists, irbesartan and valsartan. Blood Press Monit 2002; 7: 135-42.Kassler-Taub K et al. Comparative Efcacy of Two Angiotensin II Receptor Antagonist, Irbesartan and Losartan, in Mild - to - Moderate Hypertension. Am J Hypertens 1998; 11: 445-53.Kassler-Taub K et al. Comparative Efcacy of Two Angiotensin II Receptor Antagonist, Irbesartan and Losartan, in Mild - to - Moderate Hypertension. Am J Hypertens 1998; 11: 445-53.Fogari R et al. 24-Hour blood pressure control by once - daily administration of irbesartan assessed by ambulatory blood pressure monitoring. J Hypertens 1997; 15: 1511-8.Fogari R et al. 24-Hour blood pressure control by once - daily administration of irbesartan assessed by ambulatory blood pressure monitoring. J Hypertens 1997; 15: 1511-8.Neutel J.M et al. Irbesartan/HCTZ combination therapy as initial treatment for severe hypertension to achieve rapid BP control. J Hypertens 2006; 24: S284.Neutel J.M et al. Irbesartan/HCTZ combination therapy as initial treatment for severe hypertension to achieve rapid BP control. J Hypertens 2006; 24: S284.Parving H.H, Lehnert H, Brochner-Mortensen J et al. Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-8.Parving H.H, Lehnert H, Brochner-Mortensen J et al. Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-8.Lewis E.J, Hunsicker L.G, Clarke W.R et al. Renoprotective effect of the angiotensin - receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-60.Lewis E.J, Hunsicker L.G, Clarke W.R et al. Renoprotective effect of the angiotensin - receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-60.Madrid A.H, Marнn I.M, Cervantes C.E et al. Prevention of recurrences in patients with lone atrial fibrillation. The dose - dependent effect of angiotensin II receptor blockers. J Renin Angiotensin Aldosterone Syst 2004; 5 (3): 114-20.Madrid A.H, Marнn I.M, Cervantes C.E et al. Prevention of recurrences in patients with lone atrial fibrillation. The dose - dependent effect of angiotensin II receptor blockers. J Renin Angiotensin Aldosterone Syst 2004; 5 (3): 114-20.Larochelle P et al. for the Irbesartan Multicenter Investigators. Effects and tolerability of irbesartan vs enalapril in patients with severe hypertension. Am J Cardiol 1997; 80: 1613-5.Larochelle P et al. for the Irbesartan Multicenter Investigators. Effects and tolerability of irbesartan vs enalapril in patients with severe hypertension. Am J Cardiol 1997; 80: 1613-5.Julius S et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022-31.Julius S et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022-31.Neutel J.M, Saunders E, Bakris G.L et al. INCLUSIVE Investigators. The efficacy and safety of low - and high - dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial. J Clin Hypertens (Greenwich) 2005; 7 (10): 578-86.Neutel J.M, Saunders E, Bakris G.L et al. INCLUSIVE Investigators. The efficacy and safety of low - and high - dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial. J Clin Hypertens (Greenwich) 2005; 7 (10): 578-86.Kohar M et al. Matrix study of irbesartan with hydrochlorothiazide in mild - to - moderate hypertension. Am J Hypertens 1999; 12: 797-805.Kohar M et al. Matrix study of irbesartan with hydrochlorothiazide in mild - to - moderate hypertension. Am J Hypertens 1999; 12: 797-805.Hasford J et al. A population - based European cohort study of persistence in newly diagnosed hypertensive patients. J Hum Hypertens 2002; 16: 569-75.Hasford J et al. A population - based European cohort study of persistence in newly diagnosed hypertensive patients. J Hum Hypertens 2002; 16: 569-75.

The authors declare that there are no conflicts of interest present.